Back to Search
Start Over
Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatment.
- Source :
-
International Journal of Hyperthermia . Feb2012, Vol. 28 Issue 1, p33-42. 10p. 7 Graphs. - Publication Year :
- 2012
-
Abstract
- Purpose: Adding hyperthermia to chemotherapy improved the clinical outcome of patients with high risk soft tissue sarcoma. Further improvement might be possible if combined with vaccination strategies. As no sarcoma-associated antigens are known, the ectopic expression of a surrogate marker for which immune monitoring tools are available, is envisaged. We tested surrogate marker transfer into sarcoma cells in vitro using modified vaccinia virus Ankara (MVA), which has well established clinical safety. We examined its robustness against standard sarcoma treatment modalities, such as ifosfamide and hyperthermia. Materials and methods: We transduced sarcoma cell lines and primary tumour cells from sarcoma patients with MVA encoding the human tyrosinase gene (MVA-hTyr). Kinetics of tyrosinase expression and the potency to activate tyrosinase-specific cytotoxic T cells were assessed. In addition cells were exposed to chemotherapy and heat, imitating the clinical setting. Results: Tyrosinase was ectopically expressed in sarcoma cells. Infected cells presented tyrosinase epitopes for T cell recognition even if exposed to ifosfamide/heat. Conclusions: As sarcoma patients receive surgery up front or after neoadjuvant systemic chemotherapy/hyperthermia, tumour material is generally available. Our data document that primary sarcoma cells can be infected with MVA-hTyr in vitro and antigen presentation is not affected by ifosfamide or heat treatment. Infected cells can serve as a source for vaccine preparation. MVA-hTyr infection of tumour cells lacking defined antigens is a feasible system to introduce a robust surrogate marker to provide an immune monitoring marker for assessing the induction of antigen-specific T cell activation. [ABSTRACT FROM AUTHOR]
- Subjects :
- *DRUG therapy
*CANCER cells
*VIRUS diseases in cattle
*LYMPHOCYTES
*T cells
Subjects
Details
- Language :
- English
- ISSN :
- 02656736
- Volume :
- 28
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- International Journal of Hyperthermia
- Publication Type :
- Academic Journal
- Accession number :
- 70248827
- Full Text :
- https://doi.org/10.3109/02656736.2011.626834